755 results on '"Lüftner, Diana"'
Search Results
2. Das metastasierte Mammakarzinom – Hoffnungsschimmer am Horizont?
3. Neue Strategien beim metastasierten, endokrin sensitiven Mammakarzinom
4. Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective
5. Verzicht auf Sentinel-Lymphknoten-Biopsie beim frühen Mammakarzinom: bald neuer Standard?
6. The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
7. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
8. Aktuelle Strategien zur Systemtherapie des frühen Mammakarzinoms von der 18. Internationalen St.-Gallen-Konsensuskonferenz
9. Adressen
10. Malignome des Gastrointestinaltrakts
11. Erratum zu: Neue Strategien beim metastasierten, endokrin sensitiven Mammakarzinom
12. How detection of immune-related adverse events fails during transfer of patients between medical sectors
13. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
14. What do hematologists and oncologists consider necessary for their career? Results of an online survey in Germany, Austria and Switzerland
15. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer
16. Zielgerichtete Therapie im Rezidiv 1: Hormontherapie – aber nur für wenige Patientinnen
17. Karriere in der Hämatologie und medizinischen Onkologie: Identifizierung förderlicher und hinderlicher Faktoren
18. Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy
19. Return of individual genomic research results within the PRAEGNANT multicenter registry study
20. Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study
21. 49/w mit Lymphödem des Arms bei metastasiertem tripelnegativem Mammakarzinom: Vorbereitung auf die Facharztprüfung: Fall 43
22. Late Effects in Young Breast Cancer Survivors
23. Vor- und Nachteile des Mammographie-Screenings: Eine kritische Bestandsaufnahme
24. Neues zur primär systemischen Therapie des Mammakarzinoms: ESMO 2020 – SABCS 2020 – St. Gallen 2021 – ASCO 2021
25. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer
26. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs
27. Discussion of ABC7 Consensus and German Recommendations
28. Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry
29. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024
30. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study
31. New treatment options for hormone receptor positive breast cancer in 2023
32. Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie: 17. Internationale St.-Gallen-Konsensuskonferenz vor dem Hintergrund deutscher Therapieempfehlungen diskutiert
33. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
34. Immunonkologie – Für Brustkrebs doch geeignet?: Neue Ansätze beim triple-negativen Mammakarzinom
35. Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST)
36. Update Mammakarzinom 2023 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien
37. Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien
38. Systemic therapy of metastatic breast cancer: a plea for confirmation of subtypes by genomic assays
39. Die CAPTOR-BC-Studie.
40. Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
41. Stau am Östrogenrezeptor bei fortgeschrittenem Mammakarzinom: Ende der endokrinen Monotherapie
42. Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom
43. Das metastasierte Mammakarzinom ist eine chronische Erkrankung – die stabile Evidenz kam erst nach den Versprechungen
44. Checkpointinhibitoren beim metastasierten Mammakarzinom: Momentane Indikation und aktuelle Entwicklungen
45. Immuntherapeutische Therapieansätze – ein Überblick
46. Malignome des Gastrointestinaltrakts (GIT)
47. The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial
48. ABC7 Consensus: Assessment by a German Group of Experts.
49. Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies
50. Behandlung des frühen Mammakarzinoms – 18. Internationaler St.-Gallen-Konsens vor dem Hintergrund der aktuellen deutschen Therapieempfehlungen diskutiert
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.